Lv1
90 积分 2023-01-10 加入
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations
18天前
已完结
Landscape of Subcutaneous Administration Strategies for Monoclonal Antibodies in Oncology
18天前
已完结
The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases
1个月前
已完结
Differences Between Intravenous and Subcutaneous Modes of Administration in Oncology from the Patient, Healthcare Provider, and Healthcare System Perspectives: A Systematic Review
1个月前
已完结
Combination of Radiotherapy and Immunotherapy in Advanced Non–Small Cell Lung Cancer
1个月前
已完结
Durvalumab With Radiation Therapy in Patients With Inoperable Locally Advanced Non–Small Cell Lung Cancer Ineligible for Concurrent Chemoradiotherapy (DART)
1个月前
已完结
High-dose biologics and bioconjugates delivery: Integrating molecular optimization with device design and routes of administration
1个月前
已完结
Subcutaneous rituximab in indolent primary cutaneous B-cell lymphoma: A case series of 5 patients with the evaluation of the medico economic impact
2个月前
已关闭
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
2个月前
已完结
Reversing Transplant Ineligibility With Teclistamab in Ultra–High-Risk Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
2个月前
已完结
皖公网安备34019202002308
